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doi:10.101The Role of Missing Killer Cell Immunoglobulin-Like
Receptor Ligands in T Cell Replete Peripheral Blood
Stem Cell Transplantation from HLA-Identical Siblings
Johannes Clausen,1 Brigitte Kircher,1 Jutta Auberger,1 Petra Schumacher,1 Hanno Ulmer,2
Gabriele Hetzenauer,1 Dominik Wolf,1 Gu¨nther Gastl,1 David Nachbaur1The contribution of natural killer (NK) cells to graft-versus-malignancy (GVM) effects following hematopoi-
etic stem cell transplantation (HSCT) remains uncertain, particularly in the HLA-identical setting. A model
considering missing HLA ligands to the donor’s inhibitory killer cell immunoglobulin-like receptor (KIR),
termed the missing KIR ligand model, has been established in T cell depleted bone marrow transplantation
(BMT), but lacks validity in other cohorts with different treatment characteristics. We hypothesized that
the impact of missing KIR ligands on relapse-free survival (RFS) and overall survival (OS) in T cell replete pe-
ripheral blood SCT (PBSCT) differs from that in the T cell depleted BMT setting, and retrospectively evaluated
100 consecutive, HLA-identical sibling transplantations for hematologic malignancies. In addition to KIR ligand
status, we considered the donors’ activating KIRs and grafted NK, T, and CD341 cell doses. Our findings dem-
onstrate noninferiority for OS (P5 .005) and RFS (P5 .002) for the heterozygous HLA-C group KIR ligand
status (C1/2; n 5 47) compared with patients missing either C1 or C2 (n 5 53). Similarly, OS (P 5 .031)
and RFS (P 5 .034) of Bw4-positive patients was noninferior to that of patients missing a Bw4 ligand to
KIR3DL1. By multivariate analysis, C1/2 heterozygous patients had a favorable risk ratio (RR) for relapse
(RR 5 0.28; P 5 .003), RFS (RR 5 0.56; P 5 .046), and acute graft-versus-host disease grade II-IV (RR 5
0.36; P 5 .05). Following reduced-intensity conditioning (RIC), but not standard-intensity conditioning,
myeloablative (MA) transplantation, a grafted NK cell dose above the median (3.4  107/kg) was associated
with a lower risk of relapse (RR 5 0.57; P 5 .003) and improved survival (RR 5 0.78; P 5 .03). Overall, our
findings support a role for NK alloreactivity in HLA-identical HSCT, but argue against a favorable impact of
missing KIR ligands in the given setting. We conclude that the mechanism favoring the missing KIR ligand con-
stellation in T cell depleted BMT may not operate in T cell replete PBSCT. The reasons for this differential
effect remain unresolved.
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6/j.bbmt.2009.10.021extent to which natural killer (NK) cells contribute to
GVM remains a matter of debate, as does the underly-
ing immunologic model. A contribution of NK cells to
GVMwas first demonstrated inT cell depleted haploi-
dentical HSCT [1,2], where it was shown to depend on
killer cell immunoglobulin-like receptor (KIR) ligand
mismatch in graft-versus-host (GVH) direction, for ex-
ample, in the case of an HLA-C group 2 (C2)-negative
recipient with a C2-positive, KIR2DL1-positive
donor. Subsequent studies confirmed the contribution
of GVH-directed KIR ligand mismatch to NK cell
alloreactivity in unrelated HSCT [3-7], whereas other
studies did not [8-12]. The causes for these divergent
results are most likely differences in patient cohorts
and transplantation protocols, with particular regard
to T cell depletion [9,13].
In HLA-identical as opposed to HLA-mismatched
HSCT, NK alloreactivity must, by definition, rely on273
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possible mechanism, the so-called ‘‘missing KIR li-
gand’’ model, is defined by the patient’s lack of one
or more HLA class I ligands to the donor’s inhibitory
KIRs. Because of independent inheritance of KIR and
HLA genes, this constellation occurs intraindividually
(ie, it does not require an HLA mismatch), and thus it
occurs frequently in the HLA-matched setting. Stud-
ies addressing the impact of the missing KIR ligand
constellation on GVM, graft-versus-host disease
(GVHD), and graft rejection have yielded divergent
results [7,14-23]. Thus, in contrast to the KIR ligand
mismatch model for HLA-mismatched HSCT and
the conditions established to favor its clinical emer-
gence (ie, haplotype mismatch, T cell depletion, high
CD341 cell dose, and myeloid malignancy [1,9,13]),
no model has yet obtained consensual acceptance to
reliably predict NK alloreactivity in HLA-identical
HSCT. Of note, those studies showing the missing
KIR ligand model to be favorable in terms of trans-
plantation outcome were based largely on bone mar-
row (BM) and/or T cell depleted grafts [14,17,18].
Importantly, a recent study elucidating the mecha-
nisms behind the missing KIR ligand model was based
on CD341 selected HSCT [23]. In view of the forego-
ing reports and our seemingly divergent results in T
cell replete peripheral blood stem cell (PBSC) trans-
plantation (PBSCT) [20], we speculate that graft
source (BM vs PBSCs) and graft manipulation (T cell
depleted vs unmanipulated grafts) are major factors
determining whether the missing KIR ligand constel-
lation may promote or interfere with GVM effects fol-
lowing HSCT. To address this question, we restricted
the present analysis exclusively to unmanipulated
PBSC grafts.PATIENTS AND METHODS
We retrospectively evaluated 100 consecutive gran-
ulocyte-colony stimulating factor (G-CSF)–mobilized
PBSCTs from HLA-identical siblings performed for
hematologic malignancies at our institution between
October 2000 and December 2008. According to the
rules of the local ethics committee and the Declaration
of Helsinki, all patients provided written informed con-
sent before any diagnostic or treatment procedures and
agreed to anonymized handling of patient data for re-
search purposes. Treatment characteristics, described
in more detail previously [20], are summarized in Table
1. In brief, 55 patients received standard myeloablative
conditioning (MAC), and 45 patients received
reduced-intensity conditioning (RIC) because of age,
comorbidity, or previous high-dose therapy (2 alloge-
neic and 2 autologous HSCTs). GVHD prophylaxis
consisted of a trough level adjusted calcineurin inhibitor
(mainly cyclosporine-A [CsA]), and either short-coursemethotrexate (MTX; predominantly following MAC
HSCT) or mycophenolate mofetil (MMF; exclusively
following RIC HSCT). All grafts were T cell replete;
that is, neither in vivo T cell depletion (by, eg, antithy-
mocyte globulin (ATG) or alemtuzumab) nor in vitro
T cell depletion was applied.
Flow cytometric analysis of graft composition (n5
100) and KIR genotyping (n5 86), applying the poly-
merase chain reaction (PCR) single specific primer
(SSP)based KIR-Ready Gene Kit (INNO-TRAIN,
Kronberg/Taunus, Germany), have been described
previously [20]. KIR gene frequencies in the donor
cohort (Table 2) are representative for a Caucasian
population (www.allelefrequencies.net).
The missing KIR ligand constellation was evalu-
ated for the inhibitory KIRs 2DL1 (ligand to HLA-
C group 2/C2), 2DL2/3 (ligand to HLA-C group 1/
C1), 3DL1 (ligand to HLA-Bw4 epitopes including
A23, A24, and A32 [24]) and 3DL2 (ligand to HLA-
A3 and A11). Because most and virtually all Caucasians
are positive for 2DL1 and 3DL2, respectively, and at
least one of the C1-specific inhibitory KIRs 2DL2 or
2DL3, several authors have suggested evaluating for
the presence or absence of HLA-C KIR ligands
[15,16,21] or HLA-A3 and HLA-A11 KIR ligands
[20], simply assuming positivity of the cognate inhibi-
tory KIR. In the present cohort, stratification by miss-
ing C2, either considering actual donor positivity for
2DL1 (n 5 98) or assuming its positivity (n 5 100),
resulted in 95% identical strata. In case of missing
C1, both methods resulted in a 100% identical strati-
fication. In contrast, because a significant proportion
of donors (9%) did not express 3DL1, ‘‘missing
Bw4’’ was adopted only if 3DL1 was actually present
in the donor. Nevertheless, because of the frequent ex-
pression of a Bw4 epitope, 98 of 100 transplants were
evaluable for the ‘‘missing Bw4 ligand to KIR3DL1’’
condition.
The following activating KIRs were analyzed:
2DS1, 2DS2, 2DS3, 2DS4, 2DS5, and 3DS1. The
PCR kit used allows the discrimination of the 2DS4
full-length variants, *001 and *002, from the deletion
variants, *003, *004, and *006. The KIR AA genotype
was defined by the absence of any B haplotypedefining
KIR (2DL2, 2DL5, 3DS1, 2DS1, 2DS2, 2DS3, or
2DS5; www.allelefrequencies.net). The BB genotype
was assumed if the KIR A haplotypeassociated 3DL1
and 2DS4 were absent. All others were assigned to
the AB genotype.
Data were analyzed as of January 31, 2009. Statis-
tical analyses were performed using NCSS 2001 soft-
ware (NCSS, Kaysville, UT). For univariate analyses,
either Kaplan-Meier survival or cumulative incidence
analysis (considering competing risks) was applied.
Curves were compared using the log-rank test. To
address the problem of multiple comparisons, a signif-
icant difference was assumed in cases of P values# .01.
Table 1. Patient and Treatment Characteristics
Total C1/2 Heterozygous C1 or C2 Homozygous P
n 100 47 53
Follow-up of survivors, months, median (range) 38.2 (1.4–100.7) 39 (1.7–100.7) 36 (1.4–91.3) .38
Median recipient age, years (range) 49 (17–74) 47 51 .36
Median donor age, years (range) 46 (13–79) 41 49 .07
Donor/recipient sex .90
Female donor; male recipient 24 11 (23%) 13 (25%)
Other 76 36 (77%) 40 (75%)
Diagnosis .13
Acute myelogenous leukemia 43 21 (45%) 22 (42%)
Acute lymphoblastic leukemia 16 8 (17%) 8 (15%)
CML 10 5 (11%) 5 (9%)
Myelodysplastic syndrome 9 3 (6%) 6 (11%)
Lymphoma* 10 2 (4%) 8 (15%)
Myeloma† 8 7 (15%) 1 (2%)
Other 4 1 (2%) 3 (6%)
Risk category* .14
Standard risk 35 20 (43%) 15 (28%)
High risk 65 27 (57%) 38 (72%) .20
Conditioning regimen
Standard MAC 55 29 (62%) 26 (49%)
fTBI 12 Gy/Cy 24 14 10
Bu/Cy ± VP-16 25 12 13
Other 6 3 3
RIC 45 18 (38%) 27 (51%)
Bu/Flu ± thiotepa 39 16 23
Flu/TBI (2 Gy) 3 1 2
Other 3 1 2
MAC indicates myeloablative conditioning; RIC, reduced-intensity conditioning; CML, chronic myelogenous leukemia; Flu, fludarabline; Cy, cyclophos-
phamide 2 60 mg/kg i.v.; Bu, busulfan (12.8 mg/kg i.v. for MAC; 6.4 mg/kg in the majority of RIC regimens; (f)TBI, (fractionated) total body irradiation.
Standard-risk disease was defined as acute leukemia in first remission or CML in first chronic phase; all other indications were classified as high-risk
disease (see below).
*Remission state of patients with non-Hodgkin lymphoma: progressive/refractory, n5 6; relapse after HSCT, n5 3; second complete remission, n5 1.
†Remission state of patients with myeloma: progressive disease, n5 2; relapse following tandem HSCT, n5 2; relapse following allo-BMT, n5 1; partial
remission following induction therapy, n 5 3.
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EquivTest software (Statistical Solutions, Saugus,
MA) for equivalence analyses, with equivalence mar-
gins for the risk ratio (RR) set at 0.8-1.25. For
univariate analyses, graft cell counts were dichoto-
mized as ‘‘high’’ versus ‘‘low’’ according to the respec-
tive median values (Table 2). Cox regressionTable 2. Graft Composition and KIR Genotyping
Graft composition, median cell dose (range)
C
KIR gene expression (donor)
2D
2DS4 (fu
2DS4 (
KIR group haplotype frequencies (donor)
KIR indicates killer cell immunoglobulin-like receptor.multivariate analysis was calculated for overall survival
(OS; death), relapse-free survival (RFS; death or
relapse), relapse, acute GVHD (aGVHD), and
nonrelapse mortality (NRM), considering the contin-
uous variables (patient and donor age and graft
cell counts [NK cells, T cells, CD341 cells, total
mononuclear cells (MNCs)]); the categorical variablesMNC 11.8  108 (5.2–25.3  108)
D34+ cells 6.0  106 (1.1–18.2  108)
T cells 3.1  108 (1.3–7.9  108)
NK cells 3.4  107 (0.6–14.8  108)
2DL1 97%
2DL2 55%
2DL3 91%
L2 or 2DL3 100%
3DL1 91%
3DL2 100%
2DS1 35%
2DS2 56%
2DS3 30%
ll-length variant) 40%
deletion variant) 84%
2DS5 30%
3DS1 38%
AA 31%
AB 61%
BB 8%
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Figure 1. OS (A) and RFS (B) stratified by HLA-C KIR ligand group
(n 5 100).
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nor, disease risk category, and sex match [female donor
to male recipient vs other]), the missing KIR ligand
status for HLA-A, -B, and -C; and the KIR group hap-
lotype (AA vs other).
RESULTS
Impact of HLA-Inhibitory KIR Constellations
Of the 100 transplantations evaluated, 47 pairs
were C1/2 heterozygous (both HLA-C ligand groups
present), 13 pairs were C2/2 homozygous (missing
C1), and 40 pairs were C1/1 homozygous (missing
C2). The probability of OS at 3 years for the C1/2
heterozygous patients (0.58; 95% confidence interval
[CI] 5 0.42-0.74) was not inferior to that of the C1
or C2 homozygous patients (0.42; 95% CI 5 0.27-
0.57; P 5 .085 for difference; P 5 .0049 for noninfer-
iority of C1/2 heterozygosity) (Figure 1A). The prob-
ability for RFS also was not inferior in the C1/2
heterozygous patients (0.56; 95% CI 5 0.41-0.71)
compared with the C1 and C2 homozygous patients
(0.35; 95% CI 5 0.21-0.49; P 5 .035 for difference;
P 5 .002 for noninferiority of heterozygosity)
(Figure 1B). The cumulative relapse incidence at 3
years was significantly lower in the C1/2 heterozy-
gous patients (0.23; 95% CI 5 0.14-0.40) compared
with the C1 or C2 homozygous recipients (0.51;
95% CI 5 0.38-0.67; P 5 .006 for difference)
(Figure 2A). By multivariate analysis, C1/2 heterozy-
gosity was significantly associated with a lower re-
lapse incidence (RR 5 0.28; P 5 .003), had
a marginal association with superior RFS (RR 5
0.56; P 5 .046), and had an OS at least equivalent to
that of C1 or C2 heterozygosity (RR 5 0.59; P 5
.095) (Table 3).
Furthermore, the C1/2 heterozygous recipients
tended to experience less aGVHD grade II-IV com-
pared with the C1 or C2 homozygous recipients (cu-
mulative incidence, 0.11, [95% CI 5 0.05-0.25] vs
0.29 [95% CI 5 0.19-0.44]; P 5 .011) (Figure 2B).
This trend was confirmed by multivariate analysis
(RR 5 0.36; P 5 .05) (Table 3).
Similarly, with regard to KIR3DL1, the presence of
a cognate ligand (ie, Bw4 epitope) had no adverse effect
on any clinical endpoint (regardless of whether all Bw4
ligands or only those with isoleucine at residue 80
were considered; data not shown). Bw4 positivity was
not inferior to the missing Bw4 ligand constellation in
terms of OS (Bw4 present [n5 74]: 0.53, 95% CI 5
0.39-0.66; Bw4 missing [n 524]: 0.44, 95% CI 5
0.22-0.65; P 5 .031 for noninferiority) and RFS (Bw4
present [n5 74]: 0.49, 95%CI5 0.36-0.61; Bw4 miss-
ing [n 5 24]: 0.37, 95% CI 5 0.17-0.58; P 5 .034 for
noninferiority). Likewise, by multivariate analysis, the
presence or absence of a Bw4 ligand did not influence
any clinical endpoint (data not shown).The lack of both HLA-A3 andHLA-A11 (the cog-
nate ligands to KIR3DL2) had no significant effect on
RFS when the entire cohort was analyzed (n 5 62:
0.48, 95% CI 5 0.34-0.61 vs n 5 38: 0.41, 95%
CI5 0.24-0.58; P5 .44). On the other hand, noninfer-
iority of RFS and OS in the presence of HLA-A3 and/
or A11 cannot be assumed with certainty (P 5 .47 for
RFS; P 5.46 for OS). However, the effects of diverse
activating KIRs on survival were dependent on
HLA-A3/A11 status. In patients expressing HLA-A3
and/or -A11, donor positivity for KIR2DS5 was asso-
ciated with improved RFS (0.90, 95% CI 5 0.71-1.00
vs 0.21, 95% CI 5 0.03-0.39; P 5 .006) (Figure 3A)
and improved OS (0.90, 95% CI 5 0.71-1.00 vs
0.23, 95%CI5 0.04-0.42; P5 .014). This was because
of the absence of relapse in all of 10 HLA-A3 or
A11positive patients with a 2DS5-positive donor, as
opposed to a relapse incidence of 0.51 (95% CI 5
0.34-0.78) in those with 2DS5-negative donors
(P 5 .01) (Figure 3B). Multivariate analysis confirmed
the impact of a 2DS5-positive donor on RFS in the
AB
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Figure 2. Cumulative incidence of relapse (A) and aGVHD grade II-IV
(B), stratified by HLA-C KIR ligand group (n 5 100).
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KIR2DS5, KIR2DS1 had, by multivariate analysis,
a beneficial effect on OS (P 5 .05) and RFS (P 5
.026) among HLA-A3 or -A11positive patients. On
the other hand, in HLA-A3/A11negative patients,
a 2DS4 full-length variant positive donor was associ-
ated with a trend toward improved RFS (0.58, 95%
CI 5 0.33-0.82 vs 0.31, 95% CI 5 0.14-0.47;
P 5 .043).
Furthermore, expression of HLA-A3 or -A11 was
associated with a significantly increased incidence of
aGVHD grade II-IV (0.35, 95% CI 5 0.22-0.54 vs
0.12, 95% CI 5 0.06-0.23; P 5 .003) (Figure 3C), as
confirmed by multivariate analysis (P 5 .021) (Table
3). The effect of HLA-A3/11 on aGVHDwas particu-
larly pronounced in the MAC subgroup (0.41, 95%
CI 5 0.23-0.73 vs 0.11, 95% CI 5 0.04-0.27; P 5
.005). There was no association between aGVHD II-
IV and relapse incidence (RR 5 1.22; P 5 .63) or
RFS (RR5 1.03; P5 .93). Finally, the KIR group hap-
lotype (A/A vs B/x) had no significant impact on any
clinical endpoint (data not shown).Impact of the Grafted NK Cell Dose
The grafted NK cell dose (above vs below the
median [ie, 3.4  107/kg]) did not influence OS in
the entire cohort. However, after stratification for
conditioning type, differential effects were observed.
In the RIC subgroup, a high NK cell dose was associ-
ated with a trend toward lower relapse incidence (0.26,
95% CI 5 0.12-0.55 vs 0.59, 95% CI 5 0.41-0.85;
P 5 .028), superior RFS (0.50, 95% CI 5 0.27-0.72
vs 0.21, 95% CI 5 0.03-0.40; P 5 .062), and superior
OS (0.60, 95% CI 5 0.37-0.82 vs 0.22; 95% CI 5
0.03-0.41; P 5 .12). By multivariate analysis of the
RIC subgroup, a high NK cell dose improved all 3
endpoints (Table 3). Conversely, a high T cell dose
was associated with an increased relapse incidence in
the RIC subgroup (Table 3). An opposite effect of
NK cell dose was found in the MAC subgroup, with
a trend toward inferior OS after transplantations
with a high NK cell dose (0.49, 95% CI 5 0.28-0.70
vs 0.72, 95% CI 5 0.55- 0.90; P 5 .09). This trend
was confirmed by multivariate analysis (P 5 .019;
Table 3).DISCUSSION
The present study in unmanipulated, T cell replete
PBSCT failed to reproduce the GVM-promoting ef-
fect of missing KIR ligands shown previously for T
cell depleted BMT and PBSCT [14,23]. Likewise,
other studies providing evidence supporting the bene-
fit of missing KIR ligands have largely referred to
transplantations with BM as the graft source and/or in-
cluding T cell depleted grafts [17,18]. On the other
hand, 2 other studies demonstrated an adverse
outcome of C2 homozygous patients (missing C1)
following HLA-matched related HSCT [15] or
HLA-C matched unrelated HSCT [16]. Furthermore,
the effect of KIR ligands was analyzed in a cohort of
patients with chronic myelogenous leukemia (CML)
undergoing BMT or PBSCT [21]. Although not ex-
plicitly addressed by the authors, the data imply that
only those C1/2 heterozygous patients who underwent
BMT fared worse than the C1/1 and C2/2 homozy-
gous patients; those who underwent PBSCT experi-
enced a comparatively favorable course. Our data,
although limited by the heterogeneity of the diagno-
ses, are strictly homogenous with respect to the graft
source (ie, T cell replete PBSC), and show that in
this setting, C1/2 heterozygous patients have a lower
relapse risk and are not inferior to HLA-C homozy-
gous patients in terms of OS and RFS. This finding,
along with results from the aforementioned studies
[15,16,21], suggest that the benefit of missing KIR
ligands may be restricted to transplants using BM
grafts and/or applying T cell depletion. The explana-
tion for the opposing effects of KIR ligands in T cell
Table 3. Multivariate Analyses
Cohort/Endpoint Variable RR P
Entire cohort
Death C1/C2 heterozygosity 0.59 .095
Standard risk indication 0.46 .029
Donor CMV seronegativity 2.03 .025
Death or relapse C1/C2 heterozygosity 0.56 .046
Standard risk indication 0.49 .031
Relapse C1/C2 heterozygosity 0.28 .003
Standard risk indication 0.41 .053
Donor age (per year) 0.94 .023
Recipient age (per year) 1.05 .044
NRM Donor age (per year) 1.04 .04
aGVHD II-IV HLA-A3 or -A11-positive 3.00 .021
C1/C2 heterozygosity 0.36 .05
MAC subgroup
Death C1/C2 heterozygosity 0.33 .035
NK cell dose (per 107 cells) 1.53 .019
Death or relapse C1/C2 heterozygosity 0.27 .025
Recipient age (per year) 1.12 .006
Donor age (per year) 0.89 .008
Relapse C1/C2 heterozygosity 0.09 .0006
Donor age (per year) 0.84 .0003
Recipient age (per year) 1.16 .0007
RIC subgroup
Death NK cell dose (per 107 cells) 0.78 .03
Death or relapse NK cell dose (per 107 cells) 0.79 .02
Relapse NK cell dose (per 107 cells) 0.57 .003
T cell dose (per 108 cells) 1.44 .002
NRM indicates nonrelapse mortality; aGVHD, acute graft-versus-host
disease; RIC, reduced-intensity conditioning. The continuous variables
included in the multivariate analysis were recipient age, donor age,
and the graft cell counts (NK cells, T cells, CD34+ cells, total MNC).
The categorical variables were CMV serostatus of patient and donor,
disease risk category, sex match (female donor to male recipient vs
other), the missing KIR ligand status for HLA-A, -B, and -C, and the
KIR group haplotype. Only variables with a P value < .10 are listed.
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Figure 3. (A) RFS in HLA-A3 or -A11positive patients, stratified by do-
nor KIR2DS5 expression (n 5 34). (B) Cumulative incidence of relapse
in HLA-A3 or -A11positive patients, stratified by donor KIR2DS5 ex-
pression (n5 34). (C) Cumulative incidence of aGVHD grade II-IV, strat-
ified by HLA-A3 or HLA-A11 positivity (n 5 100).
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may lie in the differing reconstitution of the NK cell
compartment. In T cell depleted or CD341-selected
HSCT, reconstitution of NK cells relies largely on
the development from stem/progenitor cells. As shown
previously [23], these immature NK cells are responsi-
ble for alloreactivity, because they may respond to
missing KIR ligands before the acquisition of self-
tolerance. This may explain why Ruggeri et al. [1]
observed alloreactive NK cell clones only during the
early period after transplantation. Nonetheless, it is
theoretically possible that these ‘‘not-yet self-tolerant’’
NK cells may target physiological tissues, resulting in
GVHD to a similar extent as they mediate GVM. In
contrast, in unmanipulated PBSCT, the large number
of mature NK cells infused with the graft may
dominate the early posttransplantation period with
a self-tolerant profile.
Co-grafted T cells also may impair the recovering
NK cells by affecting their acquisition of KIR [13].
Furthermore, application of G-CSF for stem cell
mobilization may functionally alter the NK cell
compartment by mechanisms involving both CD341
progenitor cells and T cells [25]. Thus, in unmanipu-
lated PBSCT, mature (and hence self-tolerant) NKcells should not contribute to aGVHD. Nevertheless,
they have the possibility of recognizing loss or down-
regulation of HLA class I, a phenomenon frequently
observed in malignant cells [26-28]. This possibility
may be greatest if the transferred NK cells have been
Biol Blood Marrow Transplant 16:273-280, 2010 279KIR and KIR Ligands in HLA-Identical PBSCTlicensed by both C1 group and C2 group HLA, as is
the case in C1/2 heterozygous individuals, and/or by
Bw4. Accordingly, the ‘‘KIR ligand presence’’ constel-
lation would allow GVM reactivity without the need
for concomitant GVHD. Indeed, we found no associ-
ation between aGVHD and GVM effects.
The observed trend toward a reduced incidence of
aGVHD grade II-IV in C1/2 heterozygous patients
may be explained by the destruction of host antigen-
presenting cells (APCs) in the case of alloreactive
donor NK cells, as reported by Ruggeri et al. [2]. Fur-
thermore, a reduced incidence of aGVHD in C1/2
heterozygous patients has been observed in matched
related and unrelated HSCT [22].
As with KIR3DL1 missing Bw4, we did not find
a direct influence of the KIR3DL2 ligands HLA-A3
and HLA-A11 on relapse incidence or survival. This
may be due to a hyporesponsive behavior of
KIR3DL2-positive NK cells because of a low and pep-
tide-dependent affinity of KIR3DL2 to its HLA-A
ligands [29-31]. A novel finding concerning the
KIR3DL2 ligands HLA-A3 and HLA-A11 is their
modulating influence on the effects of particular acti-
vating KIRs. Most striking is the favorable outcome
in HLA-A3 or -A11positive patients in case of
a KIR2DS5 (or 2DS1)-positive donor, while HLA-
A3/11negative recipients profited by a KIR2DS4
full-length variant-positive donor. We believe that
these novel findings are worth being reexamined in
larger cohorts. Previous studies addressing the role
of donor activating KIRs revealed different effects of
either individual activating KIR genes or their cumula-
tive number [12,32-37]. Most of these studies did not
explicitly investigate the effect of the full-length forms
of KIR2DS4 (ie, *001 and *002), however. These var-
iants have been distinguished from the truncated forms
(*003, *004, and *006) by the PCR-SSP kit used in this
study. They are less frequently expressed than the
truncated forms (Table 2), as demonstrated previously
[38]. Although the full-length forms of 2DS4 are
bound to the cell because of transmembrane and cyto-
plasmatic domains, the 22-bp truncated forms, lacking
these domains, encode a soluble form of the protein.
This may explain why the functional characterization
of KIR2DS4 requires discrimination between the
full-length and the truncated variants.
Finally, our data confirm the benefit of a large
number of grafted NK cells in RIC, but not MAC,
transplantations, as has been suggested previously
[20]. Indirect support for this finding has been pro-
vided by others as well. One study revealed an associ-
ation between quantitative NK cell reconstitution
and RFS following RIC, but not MAC, transplanta-
tions [39], whereas another study on nonmyeloablative
(NMA) transplantation demonstrated associations be-
tween earlyNK cell chimerism andGVM and between
early T cell chimerism and aGVHD [40]. The reasonfor the differential impact of the NK cell dose in the
RIC and MAC settings remains to be elucidated.
We conclude that the benefit of the missing KIR
ligand constellation, as shown in the T cell depleted
setting [14,23], is not reproducible in unmanipulated
PBSCT. Thus, separate assessment of T cell depleted
versus T cell replete grafts, as well as BMT versus
PBSCT cohorts, may be needed to improve the under-
standing of KIR-related clinical effects. However,
a deeper insight into the mechanisms responsible for
the differential impact of missing KIR ligands in the
aforementioned settings will also require a sophisti-
cated analysis of NK cell function following unmanip-
ulated PBSCT in a way similar to that done previously
for T cell depleted HSCT [23].ACKNOWLEDGMENTS
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